Drugs Made In America Acquisition (DMAAR) Net Income towards Common Stockholders (2025)

Drugs Made In America Acquisition (DMAAR) posted Net Income towards Common Stockholders of -$1.8 million for Q4 2025, down 222.71% on a QoQ basis from $1.5 million in Q3 2025.

Drugs Made In America Acquisition (DMAAR) Net Income towards Common Stockholders (2025) Analysis & Trends

Drugs Made In America Acquisition's Net Income towards Common Stockholders history runs 1 years deep, the most recent figure standing at -$1.8 million for Q4 2025.

  • Quarterly Net Income towards Common Stockholders changed N/A year-over-year to -$1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.0 million (changed N/A YoY) and the FY2025 annual result came in at $2.0 million, up 805.2% from the prior year.
  • Net Income towards Common Stockholders was -$1.8 million for Q4 2025 at Drugs Made In America Acquisition, down from $1.5 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $1.6 million in Q2 2025 and bottomed at -$1.8 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 SIM Acquisition Corp. I 314.52 Mn 314.52 Mn - 507,100.00
2 Thayer Ventures Acquisition 208.29 Mn 208.29 Mn - -394,142.00
3 Newbury Street II Acquisition 185.26 Mn 185.26 Mn - 991,556.00
4 Dynamix 179.36 Mn 179.36 Mn - 1.07 Mn
5 Hallmark Venture 103.01 Mn 102.76 Mn - -
6 Voyager Acquisition 99.58 Mn 99.45 Mn - -
7 Gores Holdings X 95.80 Mn 95.37 Mn - 1.88 Mn
8 Archimedes Tech SPAC Partners 89.67 Mn 89.67 Mn - 4.61 Mn
9 Marblegate Capital 81.65 Mn 55.81 Mn - 62.45 Mn
10 Drugs Made In America Acquisition 1.37 Mn 1.37 Mn - -1.84 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -1.84 Mn
Sep 30, 2025 1.50 Mn
Jun 30, 2025 1.57 Mn
Mar 31, 2025 768,082.00